Karyopharm Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Progress
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/7/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Karyopharm Therapeutics (KPTI) PT Raised to $22 at Baird; 'Expect a transformational year'
March 15, 2018 2:01 PM EDTBaird raised its price target on Karyopharm Therapeutics (NASDAQ: KPTI) to $22.00 (from $15.00) while maintaining a Outperform rating.
Analyst Michael E. Ulz commented, "Recent progress across the selinexor franchise was highlighted, and management indicated initial commercial preparations are underway, a positive sign, in... More
Karyopharm Therapeutics (KPTI) PT Raised to $19 at Wedbush
March 15, 2018 1:57 PM EDTWedbush raised its price target on Karyopharm Therapeutics (NASDAQ: KPTI) to $19.00 (from $18.00) while maintaining an Outperform rating.
Analyst David Nierengarten commented, "KPTI has a lot riding on STORM, with success opening the doors to near-term commercialization of selinexor for MM; we... More
